Ionis Pharmaceuticals Inc [IONS] stock prices are up 0.12% to $43.03 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The IONS shares have gain 1.86% over the last week, with a monthly amount drifted -1.28%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ionis Pharmaceuticals Inc [NASDAQ: IONS] stock has seen the most recent analyst activity on July 31, 2025, when Morgan Stanley upgraded its rating to a Overweight but kept the price target unchanged to $62 for it. Previously, Barclays upgraded its rating to Overweight on July 01, 2025, and kept the price target unchanged to $57. On April 07, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $45 on the stock. Redburn Atlantic started tracking the stock assigning a Neutral rating and suggested a price target of $39 on March 31, 2025. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $60 on August 02, 2024. Leerink Partners upgraded its rating to Outperform for this stock on July 24, 2024, and upped its price target to $62.
The stock price of Ionis Pharmaceuticals Inc [IONS] has been fluctuating between $23.95 and $51.62 over the past year. Currently, Wall Street analysts expect the stock to reach $63.5 within the next 12 months. Ionis Pharmaceuticals Inc [NASDAQ: IONS] shares were valued at $43.03 at the most recent close of the market. An investor can expect a potential return of 47.57% based on the average IONS price forecast.
Analyzing the IONS fundamentals
The Ionis Pharmaceuticals Inc [NASDAQ:IONS] reported sales of 944.48M for trailing twelve months, representing a surge of 100.69%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.45 and Total Capital is -0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 42.41 points at the first support level, and at 41.78 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.53, and for the 2nd resistance point, it is at 44.02.
Ratios To Look Out For
It’s worth pointing out that Ionis Pharmaceuticals Inc [NASDAQ:IONS]’s Current Ratio is 2.87. In addition, the Quick Ratio stands at 2.86 and the Cash Ratio stands at 7.63. Considering the valuation of this stock, the price to sales ratio is 7.26, the price to book ratio is 10.84.
Transactions by insiders
Recent insider trading involved Monia Brett P, Chief Executive Officer, that happened on Jul 30 ’25 when 2432.0 shares were sold. Officer, Monia Brett P completed a deal on Jul 30 ’25 to buy 2432.0 shares. Meanwhile, Chief Executive Officer Monia Brett P sold 1160.0 shares on Jul 11 ’25.
